pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,304 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1570Endpoints1227BioSpace568Fierce Biotech563BioPharma Dive467raps194onclive165fda recalls
therapy area
allOncology10483Rare Disease2759Immunology2464Cardiology2289Hematology1888Pulmonology1879Vaccines
  • Trump pledges $90 one-time Medicare Part B premium payment to over 20 million seniors before midterms
    President Donald Trump announced on social media that more than 20 million Medicare Part B enrollees will receive a one-time $90 payment to help cover their premiums. The promise comes days before…
    STAT · 17d agoNeutral↗ source
  • Novartis pays $575 million upfront for access to Chinese biotech Abogen’s RNA platform and option on ABO-2203
    Novartis announced a deal with China‑based Abogen Biosciences that could be worth up to $7.8 billion. The agreement includes an upfront payment of $575 million. Under the deal, Abogen will provide…
    BioPharma Dive · 19d agoDealPositive↗ source
← prev
page 11 of 93
next →
103
fda medwatch93
globenewswire health73
fda press54
1646
Psychiatry & CNS1107
Ophthalmology872
Endocrinology & Metabolism691
Pain656
Nephrology645
  • Kodiak Sciences' Zenkuda shows non-inferior six-month dosing vs Eylea, shares double
    Four years ago Kodiak Sciences saw its share price plunge about 80% after its lead eye-disease candidate failed a head-to-head trial against Regeneron's Eylea, wiping out roughly $2 billion in mark…
    BioPharma Dive · 19d agoPositive readoutPositive↗ source
  • Pennsylvania reports fifth measles death as outbreak expands
    A recent report notes that Pennsylvania has recorded its fifth death linked to measles, underscoring the seriousness of the current outbreak in the state. Health officials are tracking the spread,…
    STAT · 19d agoNegative↗ source
  • Study finds modest rise in youth opioid medication use but declining six-month retention
    Researchers examined Medicaid and insurance claims for Americans aged 13 to 25 diagnosed with opioid use disorder between 2016 and 2023. The analysis, published in JAMA Network Open, aimed to asses…
    STAT · 19d agoNeutral↗ source
  • Congo Ebola outbreak kills over 4,000 as treatment center burned and health workers protest unpaid wages
    The Congo health ministry reported that the Ebola outbreak has claimed more than 4,000 lives out of 8,300 confirmed cases since it was declared in May. The death toll makes it the fastest‑growing E…
    STAT · 19d agoNegative↗ source
  • Eli Lilly rolls out LillyDirect to ship Mounjaro directly to Australian patients, sparking pharmacist concerns
    Eli Lilly announced a new service called LillyDirect that will deliver its diabetes drug Mounjaro straight to the homes of patients in Australia, bypassing the traditional pharmacy channel. The mo…
    STAT · 19d agoNeutral↗ source
  • NIH awards all grant money but delays and opaque decisions hinder researchers, cuts health disparity funding
    The National Institutes of Health announced that it has allocated the full amount of its grant budget for fiscal year 2026, but the timing and transparency of award decisions have been problematic…
    STAT · 20d agoRegulatoryNegative↗ source
  • FDA device center outlines FY 2027 guidance agenda, focusing on AI devices and change control plans
    The FDA's Center for Devices and Radiological Health announced its guidance priorities for fiscal year 2027 on Oct 1. The top items are finalizing guidance on artificial intelligence‑enabled medic…
    raps · 20d agoRegulatoryNeutral↗ source
  • Pharmacist urges law to modernize 340B discounts for multi-use orphan drugs
    A pharmacist argues that current legislation lags behind the evolving use of orphan-designated medicines, many of which now serve multiple therapeutic indications. The piece highlights the 340B dr…
    STAT · 20d agoRegulatoryNegative↗ source
  • FDA device center outlines FY 2027 guidance plan, targeting AI-enabled devices and change-control plans
    On Oct 1, the FDA’s Center for Devices and Radiological Health announced its guidance agenda for fiscal year 2027. The top priority is finalizing guidance for artificial intelligence-enabled medic…
    raps · 20d agoRegulatoryNeutral↗ source
  • Geneticist Mary-Claire King awaits Nobel call after pioneering BRCA discovery
    STAT spoke with geneticist Mary-Claire King, whose discovery of the BRCA1 and BRCA2 cancer mutations three decades ago has become a landmark in oncology. King recalled being invited to give a semi…
    STAT · 19d agoPositive↗ source
  • NIH launches streamlined website consolidating 700 sites into eight thematic hubs
    NIH announced a new version of its public website that reorganizes content from more than 700 separate sites into eight thematic hubs. The hubs cover health, research, data, clinical studies, rare…
    STAT · 19d agoPositive↗ source
  • SonoThera appoints former BridgeBio chief medical officer Adam Shaywitz
    STAT+ columnist Ed Silverman notes that the pharmaceutical industry continues to see staff changes, with a regular feature highlighting individual moves. SonoThera announced the hiring of Adam Sha…
    STAT · 19d agoNeutral↗ source
  • Doctor urges marathon organizers to adopt evidence-based heat-stroke plans as climate change raises temperatures
    A physician who treated a runner for heat stroke at the New York City Marathon says the event highlighted how extreme heat can overwhelm existing medical preparations. He urges marathon organizers…
    STAT · 20d agoNeutral↗ source
  • STAT+: Pharmalittle: We’re reading about the 340B drug pilot program, an obesity drug disappointment, and more
    The U.S. approved 10 drugmakers to participate in a 340B pilot program that will allow them to offer rebates, instead of upfront discounts, to certain providers
    STAT · 19d ago↗ source
  • Medicare Advantage plans to raise out-of-pocket costs and cut benefits for 2027 enrollees
    Medicare Advantage insurers are set to increase out-of-pocket expenses for seniors enrolling in 2027 plans. The changes include higher cost‑sharing, reduced coverage for dental and other services,…
    STAT · 20d agoNegative↗ source
  • Science journal launches special issue on women’s health, spotlighting menopause and chronic pain
    Science announced a new special issue dedicated to women’s health, released on Thursday. The collection brings together research on topics ranging from menopause to chronic pain, aiming to raise aw…
    STAT · 20d agoPositive↗ source
  • Eli Lilly, Novo, AbbVie and Boehringer showcase new obesity drug data at European meeting
    The European Association for the Study of Diabetes held its annual meeting in Milan, drawing obesity and metabolic disease experts and providing a platform for drugmakers to present emerging weight…
    BioPharma Dive · 20d agoPositive readoutPositive↗ source
  • Sanofi, Regeneron expand partnership with $1 billion deal to develop next-generation Dupixent-like antibodies
    Sanofi and Regeneron announced they have broadened their long‑standing alliance, adding a $1 billion upfront payment to fund joint work on new immune‑modulating drugs. The revised agreement calls…
    BioPharma Dive · 20d agoDealPositive↗ source
  • Pfizer's experimental eczema drug tilrekimig shows strong skin clearance in Phase 2 trial
    Pfizer reported that its three‑pronged antibody, tilrekimig, met the primary endpoint of its Phase 2 study in patients with moderate to severe atopic dermatitis. After 16 weeks, a significantly hig…
    BioPharma Dive · 20d agoPositive readoutPositive↗ source
  • Study finds GLP-1 weight-loss drugs appear safe and effective for children with severe obesity
    A transplant surgeon and obesity‑medicine specialist at NYU Langone reports that his research on GLP-1 weight‑loss drugs in children yields reassuring results. He notes that many of his transplant…
    STAT · 21d agoPositive↗ source
  • Chinese biotech firms showcase rapid drug development at Shanghai Science City conference
    Jefferies hosted its first investor conference in Shanghai’s high‑tech Science City district, gathering leaders of several fast‑growing Chinese biotech companies on a stage at the Hilton ballroom.…
    STAT · 21d agoPositive↗ source
  • Sanofi and Regeneron deepen collaboration, adding new immunology antibody program
    Sanofi and Regeneron announced an expanded partnership that builds on the success of their joint drug Dupixet, targeting a pipeline of experimental antibodies for immunological disorders. Under th…
    STAT · 21d agoDealPositive↗ source
  • HHS unveils ARPA-H SURPASS program to accelerate clinical trial design
    On Oct 1, 2026 the U.S. Department of Health and Human Services announced a new initiative under the Advanced Research Projects Agency for Health. The initiative, named the Simulation-augmented, R…
    raps · 21d agoRegulatoryNeutral↗ source